表面诱导药物多晶型成核的研究进展

doi:10.11949/0438-1157.20201482

摘要/Abstract

摘要：

表面诱导成核是指在异相成核过程中，利用异质表面与溶质分子的相互作用来调控成核过程。表面诱导成核不仅可以降低成核能垒促进成核，而且可以在不改变溶剂、温度等条件下对晶型进行调控。近年来，表面诱导成核在药物新晶型的筛选和亚稳晶型的调控两方面得到了广泛研究。本文综述了异质表面影响多晶型成核的机理，介绍了用于诱导多晶型成核的四种异质表面——聚合物、有机小分子晶体、自组装单层膜（SAMs）和凝胶，总结了四种表面选择与设计的策略。最后，对目前存在的问题进行了总结，对未来的发展进行了展望。

关键词: 药物多晶型, 表面诱导, 异相成核, 异质表面

Abstract:

Surface-induced nucleation refers to utilize the interaction between solute molecule and heterogeneous surface to regulate the nucleation process. It can not only promote the nucleation by reducing the energy requirement during the process of heterogeneous nucleation but also control crystal polymorphism while without changing solvent, temperature and so on. In recent years, surface-induced nucleation has been widely studied in screening and controlling of polymorphism of active pharmaceutical ingredients. The mechanism of heterogeneous surfaces inducing nucleation for controlling polymorphism is reviewed. In addition, four surface substrates used to induce nucleation for controlling crystal polymorphism including polymers, small organic molecular crystals, self-assembled monolayers and gels are reviewed. Besides, four strategies for selection and design of surface substrates are summarized. At last, we introduce the existing problems about surface-induced nucleation of polymorphism and prospect the future development of this research field.

Key words: drug polymorphism, surface-induce, heterogeneous nucleation, heterogeneous surface

中图分类号:

TQ 460.1

林家伟, 石鹏, 龚俊波, 吴送姑. 表面诱导药物多晶型成核的研究进展[J]. 化工学报, 2021, 72(2): 814-827.

LIN Jiawei, SHI Peng, GONG Junbo, WU Songgu. Progress on surface-induced nucleation of drug for controlling polymorphism[J]. CIESC Journal, 2021, 72(2): 814-827.

图/表 6

参考文献 75

1	Higashi K, Ueda K, Moribe K. Recent progress of structural study of polymorphic pharmaceutical drugs[J]. Advanced Drug Delivery Reviews, 2017, 117: 71-85.
2	吴送姑. 药物晶型转化过程分析与控制研究[D]. 天津: 天津大学, 2017.
	Wu S G. Analysis and control of polymorphism transformation process of drug [D]. Tianjin: Tianjin University, 2017.
3	Shi P, Xu S J, Du S C, et al. Insight into solvent-dependent conformational polymorph selectivity: the case of undecanedioic acid[J]. Crystal Growth and Design, 2018, 18(10): 5947-5956.
4	Fandaruff C, Rauber G S, Araya-Sibaja A M, et al. Polymorphism of anti-HIV drug efavirenz: investigations on thermodynamic and dissolution properties[J]. Crystal Growth & Design, 2014, 14(10): 4968-4975.
5	Martino P D, Guyot-Hermann A M, Conflant P, et al. A new pure paracetamol for direct compression: the orthorhombic form [J]. International Journal of Pharmaceutics, 1996, 128(1/2): 1-8.
6	Karmwar P, Graeser K, Gordon K C, et al. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods[J]. International Journal of Pharmaceutics, 2011, 417(1/2): 94-100.
7	Cui P L, Yin Q X, Guo Y H, et al. Polymorphic crystallization and transformation of candesartan cilexetil[J]. Industrial & Engineering Chemistry Research, 2012, 51(39): 12910-12916.
8	Beckmann W. Seeding the desired polymorph: background, possibilities, limitations and case studies[J]. Org. Process Res. Dev., 2000, 4(5): 372-383.
9	Mo Y X, Dang L P, Wei H Y. L-Glutamic acid polymorph control using amino acid additives[J]. Industrial ＆ Engineering Chemistry Research, 2011, 50(18): 10385-10392.
10	Simone E, Steele G, Nagy Z K. Tailoring crystal shape and polymorphism using combinations of solvents and a structurally related additive[J]. CrystEngComm, 2015, 17(48): 9370-9379.
11	Weissbuch I, Leisorowitz L, Lahav M. “Tailor-Made” and charge-transfer auxiliaries for the control of the crystal polymorphism of glycine[J]. Advanced Materials, 1994, 6(12): 952-956.
12	Dowling R, Davey R J, Curtis R A, et al. Acceleration of crystal growth rates: an unexpected effect of tailor-made additives[J]. Chemical Communications, 2010, 46(32): 5924-5926.
13	Du W, Yin Q X, Gong J B, et al. Effects of solvent on polymorph formation and nucleation of prasugrel hydrochloride[J]. Crystal Growth and Design, 2014, 14(9): 4519-4525.
14	Wu S G, Chen M Y, Rohani S, et al. Solvent-mediated nonoriented self-aggregation transformation: a case study of gabapentin[J]. Crystal Growth and Design, 2017, 17(8): 4207-4216.
15	Tang W W, Mo H P, Zhang M T, et al. Glycine's pH-dependent polymorphism: a perspective from self-association in solution[J]. Crystal Growth and Design, 2017, 17(10): 5028-5033.
16	Shen S, Xia G M, Jiang Z J, et al. Temperature controlling polymorphism and polymorphic interconversion in sublimation crystallization of 5-methoxy-salicylaldhyde azine[J]. Crystal Growth and Design, 2019, 19(1): 320-327.
17	Tang W W, Sima A D, Gong J B, et al. Kinetic difference between concomitant polymorphism and solvent-mediated phase transformation: a case of tolfenamic acid[J]. Crystal Growth and Design, 2020, 20(3): 1779-1788.
18	Karavassili F, Valmas A, Dimarogona M, et al. Exploring the complex map of insulin polymorphism: a novel crystalline form in the presence of m-cresol[J]. Acta Crystallographica Section D: Structural Biology, 2020, 76: 366-374.
19	Ventura S P M, Silva F A E, Quental M V, et al. Ionic-liquid-mediated extraction and separation processes for bioactive compounds: past, present, and future trends[J]. Chemical Reviews, 2017, 117(10): 6984-7052.
20	Martins I C B, Gomes J R B, Duarte M T, et al. Understanding polymorphic control of pharmaceuticals using imidazolium-based ionic liquid mixtures as crystallization directing agents[J]. Crystal Growth and Design, 2017, 17 (2): 428-432.
21	An J H, Jin F, Kim H S, et al. Investigation of the polymorphic transformation of the active pharmaceutical ingredient clopidogrel bisulfate using the ionic liquid AEImBF(4)[J]. Crystal Growth and Design, 2016, 16(4): 1829-1836.
22	An J H, Kim W S. Antisolvent crystallization using ionic liquids as solvent and antisolvent for polymorphic design of active pharmaceutical ingredient[J]. Crystal Growth and Design, 2013, 13(1): 31-39.
23	Ding L, Zong S H, Dang L P, et al. Effects of inorganic additives on polymorphs of glycine in microdroplets[J]. CrystEngComm, 2018, 20(2): 164-172.
24	Laval P, Giroux C, Leng J, et al. Microfluidic screening of potassium nitrate polymorphism[J]. Journal of Crystal Growth, 2008, 310(12): 3121-3124.
25	Thakore S D, Sood A, Bansal A K. Emerging role of primary heterogeneous nucleation in pharmaceutical crystallization[J]. Drug Development Research, 2020, 81(1): 3-22.
26	Artusio F, Pisano R. Surface-induced crystallization of pharmaceuticals and biopharmaceuticals: a review[J]. International Journal of Pharmaceutics, 2018, 547(1/2): 190-208.
27	Sun X Y, Garetz B A, Myerson A S. Supersaturation and polarization dependence of polymorph control in the nonphotochemical laser-induced nucleation (NPLIN) of aqueous glycine solutions[J]. Crystal Growth & Design, 2006, 6(3): 684-689.
28	Parambil J V, Poornachary S K, Heng J Y Y, et al. Template-induced nucleation for controlling crystal polymorphism: from molecular mechanisms to applications in pharmaceutical processing[J]. CrystEngComm, 2019, 21(28): 4122-4135.
29	Kulkarni S A, Weber C C, Myerson A S, et al. Self-association during heterogeneous nucleation onto well-defined templates[J]. Langmuir, 2014, 30(41): 12368-12375.
30	Mitchell C A, Yu L, Ward M D. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates[J]. Journal of the American Chemical Society, 2001, 123(44): 10830-10839.
31	Bonafede S J, Ward M D. Selective nucleation and growth of an organic polymorph by ledge-directed epitaxy on a molecular crystal substrate[J]. Journal of the American Chemical Society, 1995, 117: 7853-7861.
32	Olmsted B K, Ward M D. The role of chemical interactions and epitaxy during nucleation of organic crystals on crystalline substrates[J]. CrystEngComm, 2011, 13(4): 1070-1073.
33	Hamilton B D, Ha J M, Hillmyer M A, et al. Manipulating crystal growth and polymorphism by confinement in nanoscale crystallization chambers[J]. Accounts of Chemical Research, 2013, 45(3): 412-413.
34	Page A J, Sear R P. Crystallization controlled by the geometry of a surface[J]. Journal of the American Chemical Society, 2009, 131: 17550-17551.
35	Delmas T, Shah U V, Roberts M M, et al. Crystallisation of the orthorhombic form of acetaminophen: combined effect of surface topography and chemistry[J]. Powder Technology, 2013, 236: 24-29.
36	Beiner M, Rengarajan G T, Pankaj S, et al. Manipulating the crystalline state of pharmaceuticals by nanoconfinement[J]. Nano Letters, 2007, 7(5): 1381-1385.
37	Hamilton B D, Weissbuch I, Lahav M, et al. Manipulating crystal orientation in nanoscale cylindrical pores by stereochemical inhibition[J]. Journal of the American Chemical Society, 2009, 131(7): 2588-2596.
38	López-Mejías V, Myerson A S, Trout B L. Geometric design of heterogeneous nucleation sites on biocompatible surfaces[J]. Crystal Growth and Design, 2013, 13(8): 3835-3841.
39	Gianluca D P, Enrica F, Efrem C, et al. From tailored supports to controlled nucleation: exploring material chemistry, surface nanostructure, and wetting regime effects in heterogeneous nucleation of organic molecules[J]. Crystal Growth and Design, 2012, 12(7): 3749-3757.
40	Page A J, Sear R P. Heterogeneous nucleation in and out of pores[J]. Physical Review Letters, 2006, 97(6): 1-4.
41	Ha J M, Wolf J H, Hillmyer M A, et al. Polymorph selectivity under nanoscopic confinement[J]. Journal of the American Chemical Society, 2004, 126(11): 3382-3383.
42	Delmas T, Shah U V, Roberts M M, et al. Crystallisation of the orthorhombic form of acetaminophen : combined effect of surface topography and chemistry[J]. Powder Technology, 2013, 236: 24-29.
43	Caridi A, Kulkarni S A, Profio D G, et al. Template-induced nucleation of isonicotinamide polymorphs[J]. Crystal Growth and Design, 2014, 14(3): 1135-1141.
44	Lang M D, Grzesiak A L, Matzger A J. The use of polymer heteronuclei for crystalline polymorph selection[J]. Journal of the American Chemical Society, 2002, 124(50): 14834-14835.
45	Roy S, Goud N R, Matzger A J. Polymorphism in phenobarbital: discovery of a new polymorph and crystal structure of elusive form V[J]. Chemical Communications, 2016, 52: 4389-4392.
46	López-Mejías V, Kampf J W, Matzger A J. Nonamorphism in flufenamic acid and a new record for a polymorphic compound with solved structures[J]. Journal of the American Chemical Society, 2012, 134(24): 9872-9875.
47	López-Mejías V, Knight J L, Brooks C L, et al. On the mechanism of crystalline polymorph selection by polymer heteronuclei[J]. Langmuir, 2011, 27(12): 7575-7579.
48	Song Y, Wu Y T, Jiang Y P, et al. Polymers and solvent-induced polymorphic selection and preferential orientation of pyrazinamide crystal[J]. Crystal Growth and Design, 2020, 20(1): 352-361.
49	McKellar S C, Urquhart A J, Lamprou D A, et al. Polymer templating of supercooled indomethacin for polymorph selection[J]. ACS Combinatorial Science, 2012, 14(3): 155-159.
50	刘安元. 甲糖宁多晶型的调控研究[D].天津: 天津大学, 2012.
	Liu A Y. The screening study of tolbutamide polymorphs[D]. Tianjin: Tianjin University, 2012.
51	李妍, 吴宇嘉, 刘涛, 等.有机晶体多晶型调控研究进展[J].化学工程, 2013, 41(9): 31-35.
	Li Y, Wu Y J, Liu T, et al. Progress on controlling organic crystal polymorphs[J]. Chemical Engineering(China), 2013, 41(9): 31-35.
52	Cox J R, Dabros M, Shaffer J A, et al. Selective crystal growth of the anhydrous and monohydrate forms of theophylline on self-assembled monolayers[J]. Angew. Chem. Int. Ed., 2007, 46(12): 1988-1991.
53	Quist F, Mooney J, Kakkar A K. Self-assembled monolayers: solidification of carbamazepine in form II at an interface[J]. Colloids and Surfaces B-Biointerfaces, 2008, 62(2): 319-323.
54	Yang X C, Sarma B, Myerson A S. Polymorph control of micro/nano-sized mefenamic acid crystals on patterned self-assembled monolayer islands[J]. Crystal Growth and Design, 2012, 12(11): 5521-5528.
55	Hiremath R, Varney S W, Swift J A. Oriented crystal growth of 4-iodo-4′-nitrobiphenyl on polar self-assembled monolayer templates: a case for “chemical epitaxy”[J]. Chemistry of Materials, 2004, 16(24): 4948-4954.
56	Cox J R, Ferris L A, Thalladi V R. Selective growth of a stable drug polymorph by suppressing the nucleation of corresponding metastable polymorphs[J]. Angewandte Chemie-International Edition, 2007, 46(23): 4333-4336.
57	Bolla G, Myerson A S. SURMOF induced polymorphism and crystal morphological engineering of acetaminophen polymorphs: advantage of heterogeneous nucleation[J]. CrystEngComm, 2018, 20(15): 2084-2088.
58	Arlin J, Price L S, Price L, et al. A strategy for producing predicted polymorphs: catemeric carbamazepine form V[J]. Chemical Communications, 2011: 7074-7076.
59	Zhang K K, Xu S J, Gong J B, et al. Revealing the critical role of template functional group ordering in the template-directed crystallization of pyrazinamide[J]. CrystEngComm, 2019, 21(42): 6382-6389.
60	Park Y, Boerrigter S X M, Yeon J, et al. New metastable packing polymorph of donepezil grown on stable polymorph substrates[J]. Crystal Growth and Design, 2016, 16(5): 2552-2560.
61	Diao Y, Whaley K E, Helgeson M E, et al. Gel-induced selective crystallization of polymorphs[J]. Journal of the American Chemical Society, 2012, 134(1): 673-684.
62	Kaufmann L, Kennedy S R, Jones C D, et al. Cavity-containing supramolecular gels as a crystallization tool for hydrophobic pharmaceuticals[J]. Chemical Communications, 2016, 52(66): 10113-10116.
63	Aparicio F, Matesanz E, Sánchez L. Cooperative self-assembly of linear organogelators. Amplification of chirality and crystal growth of pharmaceutical ingredients[J]. Chemical Communications, 2012, 48(46): 5757-5759.
64	张文铖, 龚俊波, 董伟兵, 等.凝胶对结晶过程影响的研究进展[J].化工学报, 2020, 71(2): 487-499.
	Zhang W C, Gong J B, Dong W B, et al. Research progress in effect of gel on crystallization process[J]. CIESC Journal, 2020, 71(2): 487-499.
65	Foster J A, Damodaran K K, Maurin A, et al. Pharmaceutical polymorph control in a drug-mimetic supramolecular gel[J]. Chemical Science, 2017, 8(1): 78-84.
66	Araya-Sibaja A M, Soldi V, de Campos C E M, et al. Crystal growth of progesterone metastable and stable polymorphs by polymer induced herteronucleation (PIHn) method[J]. Crystal Research and Technology, 2016, 51(1): 49-57.
67	Banerjee M, Saraswatula S, Willows L G, et al. Pharmaceutical crystallization in surface-modified nanocellulose organogels[J]. Journal of Materials Chemistry B, 2018, 6(44): 7317-7328.
68	Wijethunga T K, Chen X, Myerson A S, et al. The use of biocompatible crystalline substrates for the heterogeneous nucleation and polymorphic selection of indomethacin[J]. CrystEngComm, 2019, 21(13): 2193-2202.
69	Bora P, Saikia B, Sarma B. Oriented crystallization on organic monolayers to control concomitant polymorphism[J]. Chemistry-A European Journal, 2020, 26(3): 699-710.
70	Li J J, Bourne S A, Caira M R. New polymorphs of isonicotinamide and nicotinamide[J]. Chemical Communications, 2011, 47(5): 1530-1532.
71	Zhang K K, Xu S J, Liu S Y, et al. Novel strategy to control polymorph nucleation of gamma pyrazinamide by preferred intermolecular interactions during heterogeneous nucleation[J]. Crystal Growth and Design, 2018, 18(9): 4874-4879.
72	Srirambhatla V K, Guo R, Price S L, et al. Isomorphous template induced crystallisation: a robust method for the targeted crystallisation of computationally predicted metastable polymorphs[J]. Chemical Communications, 2016, 52(46): 7384-7386.
73	Lee E H, Boerrigter S X M, Byrn S R. Epitaxy of a structurally related compound on the (100) faces of flufenamic acid form Ⅰ and Ⅲ single crystals[J]. Crystal Growth and Design, 2010, 10(2): 518-527.
74	Diao Y, Harada T, Myerson A S, et al. The role of nanopore shape in surface-induced crystallization[J]. Nature Materials, 2011, 10(11): 867-871.
75	Tan L, Davis R M, Myerson A S, et al. Control of heterogeneous nucleation via rationally designed biocompatible polymer surfaces with nanoscale features[J]. Crystal Growth and Design, 2015, 15(5): 2176-2186.